UiPath Inc. (NYSE:PATH) Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. trimmed its position in shares of UiPath Inc. (NYSE:PATH) by 6.9% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 185,932 shares of the healthcare company’s stock after selling 13,887 shares during the period. Oppenheimer & Co. Inc.’s holdings in UiPath were worth $2,358,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank purchased a new stake in UiPath during the fourth quarter worth about $165,749,000. Vanguard Group Inc. increased its stake in UiPath by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock worth $911,741,000 after buying an additional 2,133,078 shares during the period. Artisan Partners Limited Partnership acquired a new stake in UiPath during the 4th quarter worth approximately $48,267,000. First Trust Advisors LP boosted its position in UiPath by 122.6% in the 4th quarter. First Trust Advisors LP now owns 1,132,984 shares of the healthcare company’s stock valued at $28,143,000 after buying an additional 624,003 shares during the period. Finally, Trexquant Investment LP grew its stake in shares of UiPath by 303.7% in the fourth quarter. Trexquant Investment LP now owns 741,506 shares of the healthcare company’s stock worth $18,419,000 after acquiring an additional 557,828 shares in the last quarter. 62.50% of the stock is currently owned by hedge funds and other institutional investors.

UiPath Trading Down 0.2 %

UiPath stock opened at $12.48 on Tuesday. The company’s 50-day moving average price is $12.11 and its two-hundred day moving average price is $16.14. The stock has a market cap of $7.15 billion, a price-to-earnings ratio of -78.00 and a beta of 0.87. UiPath Inc. has a 52 week low of $10.37 and a 52 week high of $27.87.

UiPath (NYSE:PATH) last announced its earnings results on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01. UiPath had a negative return on equity of 3.98% and a negative net margin of 8.13%. The business had revenue of $316.00 million during the quarter, compared to analysts’ expectations of $303.69 million. During the same quarter last year, the business posted ($0.09) earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. Research analysts expect that UiPath Inc. will post -0.23 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PATH has been the subject of several recent research reports. BMO Capital Markets lifted their price objective on UiPath from $14.00 to $15.00 and gave the company a “market perform” rating in a research note on Friday, September 6th. Scotiabank dropped their price objective on UiPath from $30.00 to $25.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 29th. Needham & Company LLC reissued a “hold” rating on shares of UiPath in a report on Friday, September 6th. Evercore ISI upped their target price on UiPath from $13.00 to $16.00 and gave the company an “in-line” rating in a research report on Friday, September 6th. Finally, JPMorgan Chase & Co. cut their price target on UiPath from $28.00 to $19.00 and set an “overweight” rating on the stock in a research report on Thursday, May 30th. Sixteen investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, UiPath has a consensus rating of “Hold” and a consensus target price of $17.71.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.